RT Journal Article
T1 Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation.
T2 Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada.
A1 Aomar-Millán, Ismael Francisco
A1 Salvatierra, Juan
A1 Torres-Parejo, Úrsula
A1 Nuñez-Nuñez, María
A1 Hernández-Quero, José
A1 Anguita-Santos, Francisco
K1 COVID-19
K1 Cytokine storm syndrome
K1 Inflamación
K1 Inflammation
K1 Methylprednisolone
K1 Metilprednisolona
K1 Síndrome de tormenta de citoquinas
K1 Tocilizumab
AB To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation. A retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divided into three treatment groups (pulses of methylprednisolone alone [groupI], tocilizumab alone [groupII] and methylprednisolone plus tocilizumab [groupIII]). The aim was to assess intergroups differences in the clinical course with a 60-day follow-up and related analytical factors. 14 patients (9,8%) died: 8 (10%) in groupI and 6 (9,5%) in groupsII andIII. 15 (10,6%) were admitted to ICU: 2 (2,5%) from groupI, 4 (28,5%) from groupII and 9 (18,4%) from groupIII. The mean hospital stay was longer in groupII and clinical outcome was not associated with treatment. Tocilizumab seems to be not associated with better clinical outcomes and should be reserved for clinical trial scenario, since its widespread use may result in higher rate of ICU admission and longer mean hospital stay without differences in mortality rate and potentially adverse events.
YR 2021
FD 2021-01-28
LK http://hdl.handle.net/10668/17226
UL http://hdl.handle.net/10668/17226
LA en
LA es
DS RISalud
RD Apr 9, 2025